multiple sclerosis

Biomedicine

Daclizumab – Manipulating the immune system in unexpected ways

23rd January 201728th July 2019

Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown […]

Search for:

Stay in the loop

Click to subscribe to the newsletter

This website uses cookies to improve your experience. We'll assume you're OK with this, but you can opt-out if you wish. Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Privacy Overview

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.